Glenmark receives USFDA approval for generic version of Mycolog-II

25 Oct 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/g, the generic version of Mycolog-II (nystatin and triamcinolone acetonide) Cream, 100,000 units/g, 0.1%, of Delcor Asset Corporation (which is no longer being marketed in the United States).

According to IMS Health sales data for the 12 month period ending August 2016, the Mycolog-II (nystatin and triamcinolone acetonide) Cream, 100,000 units/g, 0.1% market achieved annual sales of approximately $120.9 million.

Glenmark’s current portfolio consists of 111 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1974.05 17.65 (0.90%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×